Core Insights - Alibaba Health and Eli Lilly China have formed a strategic partnership to focus on chronic disease management, particularly diabetes, through digital patient support, physician-patient education, and collaborative innovation [1][3]. Group 1: Industry Context - The burden of chronic diseases, particularly diabetes, is increasing in China, with approximately 148 million adult diabetes patients reported in 2022, accounting for 18% of the global adult diabetes population [3]. - Among diabetes patients aged 30 and above, 78 million remain untreated, highlighting significant gaps in disease management [3]. - The management rate for key chronic diseases in China is below 60%, with patients facing challenges such as discontinuity in out-of-hospital management, unstable drug supply, and lack of professional guidance [3]. Group 2: Company Initiatives - Alibaba Health, as a leading online healthcare platform, has a reach of over 300 million users and an efficient pharmaceutical supply chain network covering hundreds of cities across China [3]. - The company offers comprehensive post-diagnosis disease management services, including medication guidance, lifestyle interventions, and follow-up services, creating a full-cycle health management solution [3]. - Alibaba Health has introduced customized temperature-controlled logistics for innovative drugs requiring cold chain transport, ensuring compliance, safety, and efficiency throughout the storage and delivery process [3]. Group 3: Eli Lilly's Role - Eli Lilly has a nearly 150-year history with strong research and innovation capabilities in the field of endocrine metabolism [4]. - As one of the first multinational pharmaceutical companies to enter the Chinese market, Eli Lilly actively promotes the localization of innovative therapies and participates in the construction of China's chronic disease prevention and control system [4].